ApoB: The Cholesterol Number Your Doctor Probably Is Not Ordering
LDL cholesterol measures how much cholesterol is carried in LDL particles; ApoB reflects the number of atherogenic particles themselves. Each of these particles carries one ApoB molecule, and there is substantial evidence that ApoB measures the risk from them more accurately than LDL cholesterol.6 Here is what the studies show, including where ApoB's advantage is smaller than often claimed.
- Very low-density, low-density and lipoprotein(a) particles each carry one ApoB molecule, so ApoB reflects the number of atherogenic particles, while the cholesterol carried per particle varies.6
- In the Framingham Offspring Study, LDL particle number was more strongly related to future cardiovascular disease than LDL cholesterol or non-HDL cholesterol, and each particle carried less cholesterol when triglycerides were high.3
- In INTERHEART, a raised ApoB/ApoA1 ratio was linked to more than three times the odds of a heart attack (top versus bottom fifth) across 52 countries.4
- The 2026 US dyslipidemia guideline, which replaced the 2018 cholesterol guideline, supports selective ApoB testing, which may help find remaining risk when LDL cholesterol looks controlled.7,8
- In people already taking statins, on-treatment non-HDL cholesterol predicted future events better than either LDL cholesterol or ApoB, which performed similarly.5
The standard lipid panel of total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides remains the basis of cardiovascular risk assessment. It measures the cholesterol carried in lipoprotein particles rather than the number of particles, which is the dimension ApoB adds.6
LDL cholesterol measures the total amount of cholesterol carried by LDL particles, not how many particles there are. Cholesterol can only enter the artery wall inside ApoB particles, and because the cholesterol per particle varies, two people with the same LDL cholesterol can carry different numbers of particles.6
What ApoB Actually Measures
Very low-density lipoprotein, LDL, chylomicron and lipoprotein(a) particles each contain one molecule of ApoB, so an ApoB measurement reflects the total number of these particles in the blood.6
In a meta-analysis of 12 studies with 233,455 people and 22,950 cardiovascular events, ApoB was the strongest marker of risk (a standardized relative risk ratio of 1.43), LDL cholesterol the weakest (1.25) and non-HDL cholesterol in between (1.34).2
Why LDL-C and ApoB Diverge: The Discordance Problem
LDL cholesterol and ApoB usually move together but can diverge in individuals. In the Framingham Offspring Study of 3,066 adults followed for a median of 14.8 years, the cholesterol carried per LDL particle was lower when triglycerides were higher, and LDL particle number was more strongly related to future cardiovascular disease than LDL cholesterol or non-HDL cholesterol.3
Because the cholesterol per particle falls as triglycerides rise, LDL cholesterol is most likely to understate the number of particles when triglycerides are high.3
ApoB vs LDL-C: What the Evidence Shows
INTERHEART enrolled 15,152 people with a first heart attack and 14,820 controls in 52 countries. A raised ApoB/ApoA1 ratio carried an odds ratio of 3.25 for the top versus the lowest fifth and accounted for an estimated 49.2% of the population risk, alongside smoking (odds ratio 2.87 for current versus never smokers).4
The advantage is not universal. In individual data from 62,154 patients in eight statin trials, on-treatment LDL cholesterol, non-HDL cholesterol and ApoB were each linked to future major cardiovascular events, but the link was strongest for non-HDL cholesterol, with no significant difference between ApoB and LDL cholesterol.5
What the Guideline Says
The 2026 US dyslipidemia guideline replaced the 2018 cholesterol guideline, which had listed an ApoB of 130 mg/dL or more among the risk-enhancing factors favouring a statin.7,1 The 2026 guideline refines risk with selective measurement of ApoB, lipoprotein(a) and coronary calcium, and notes that non-HDL cholesterol and ApoB may help identify remaining risk when LDL cholesterol appears controlled.8
How to Lower ApoB
Under the 2026 guideline, a 30% to 49% reduction in LDL cholesterol is generally appropriate at borderline or intermediate 10-year risk and at least 50% at high risk, alongside LDL goals that are generally below 100 mg/dL and below 70 mg/dL respectively.8 Which treatment fits your risk is a decision to make with a clinician.
ApoB is a standard blood test offered by commercial laboratories and can be added to a routine lipid panel. Ask your clinician to include it, especially if your triglycerides are high.
Put this research into practice: Biomarker Reference Tool · Lab Results Interpreter
References
- 1Grundy SM, et al. "2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines." Circulation. 2019;139(25):e1082-e1143. PubMed · DOI
- 2Sniderman AD, et al. "A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk." Circ Cardiovasc Qual Outcomes. 2011;4(3):337-45. PubMed · DOI
- 3Cromwell WC, et al. "LDL Particle Number and Risk of Future Cardiovascular Disease in the Framingham Offspring Study - Implications for LDL Management." J Clin Lipidol. 2007;1(6):583-92. PubMed · DOI
- 4Yusuf S, et al. "Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study." Lancet. 2004;364(9438):937-52. PubMed · DOI
- 5Boekholdt SM, et al. "Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis." JAMA. 2012;307(12):1302-9. PubMed · DOI
- 6Sniderman AD, et al. "Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review." JAMA Cardiol. 2019;4(12):1287-1295. PubMed · DOI
- 7Blumenthal RS, et al. "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines." Circulation. 2026;153(17):e1154-e1276. PubMed · DOI
- 8Sabouret P, et al. "The 2026 ACC/AHA Dyslipidemia Guideline: A Critical and Transatlantic Perspective on Personalized Lipid Management." Life (Basel). 2026;16(9). PubMed · DOI